Enersense won a contract with Fingrid to build the 400/110 kV transformer substation and related pow...
Inledningen av 2025 var i linje med våra förväntningar.
Redeye is positive to GomSpace’s trading update published this morning, which included solid growth ...
Sales trough reached, return to EBIT growth in Q3e '25e-'27e EBIT down 29-13% on FX and system sales...
Suominen Q1 comparable EBITDA of EUR 4.1m came fairly in line with Vara Research consensus expectati...
Redeye provides an initial comment on the Q1 2025 report from Cheffelo, which was in line with annou...
Redeye returns with an update following AlzeCure's Q1 2025 earnings release, which aligned with our ...
Investors House reported Q1 revenues of EUR 2.7m, 4% below our estimate.
Redeye returns with a more in-depth take on OssDsign’s Q1 report.
Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 proje...
Redeye comments on Combinedx’s Q1 report, showing solid profitability yet somewhat lower sales than ...
Redeye updates its estimates following Freemelt’s Q1 report, which came in lower than expected in te...
Redeye provides an update following Optomed’s Q1 2025 report.
Redeye updates its estimates and fair value range following CTEK’s Q1 results, which exceeded our ex...
Redeye provides an update on Scandinavian ChemoTech following the Q1 2025 report.
Redeye comments on the outcome of AcouSort’s rights issue.
NoHo Partners' Q1 2025 results missed Vara Research expectations on several items, but we argue that...
Redeye retains its view of Hanza following a Q1 report showing a relatively solid performance in a s...
Impressive margin lift in both segments, EBITA +6% vs.
Soft Q1 sales of SEK 2.9m on no machine deliveries, but 6 orders Share issue readies balance sheet f...
